Key Takeaways for IQVIA Stock as of July 2026
- Adjusted Beat, Cash Flow Miss: IQVIA posted Q2 revenue of $4.368B (+8.74% YoY, beating estimates by 1.53%) and adjusted EPS of $3.15 (+12.10% YoY, beating by 3.94%), but free cash flow of $360M missed estimates by 9.75% and GAAP EPS of $1.53 missed by 19.49%.
- Guidance Raised: Management lifted FY2026 revenue guidance to $17.275B-$17.475B (~7% YoY at midpoint) and adjusted EPS guidance to $12.80-$13.00 (~8% YoY at midpoint).
- Bookings Surge: R&D Solutions net new bookings jumped 19.3% YoY to $3.15B, a 1.22x book-to-bill.
- “Cleanest Quarter” Claim: CEO Ari Bousbib called Q2 the cleanest quarter of his 25-year career, saying “nothing salient, unusual, abnormal, odd, awkward” showed up anywhere in the numbers.
IQV stock beat on revenue and adjusted EPS but missed on GAAP profit and free cash flow. Dig into every reported line, analyze IQV stock on TIKR for free →
IQVIA’s “Cleanest Quarter” Delivers a Beat With a Cash Flow Catch
IQVIA Holdings (IQV) posted second-quarter revenue of $4.368 billion on July 28, up 8.74% year over year and 1.53% above estimates heading into the print. Organic growth accelerated to 6% for the company as a whole, three times the pace it delivered a year earlier, and every headline metric in the release cleared the high end of management’s own guidance range. IQVIA stock still closed at $235 on July 31, down 1.16% for the session, a muted reaction given the scope of the beat.
Research and development solutions (R&DS), the clinical trial and outsourcing segment, grew revenue 8.8% to $2.575 billion, but the sharper signal sat in bookings. Net new bookings hit $3.15 billion, up 19.3% year over year, pushing the book-to-bill ratio to 1.22 times in a quarter where revenue itself grew almost 9%. That combination matters because R&DS runs on long, multi-year contracts. Trailing 12-month net new bookings reached $11.25 billion, up 12.9% year over year, and management flagged that figure as the fourth straight quarter of acceleration.
Commercial Solutions, the marketing and patient-engagement segment, grew revenue 8.6% to $1.793 billion, with analytics and consulting posting its fastest organic growth since 2022. Adjusted EBITDA reached $994 million, up 9.2% year over year, as 90 basis points of operational productivity gains offset an 80 basis point drag from pass-through revenue growth. Adjusted diluted EPS climbed 12.10% year over year to $3.15, a beat wide enough that CFO Mike Fedock found nothing unusual to call out in the quarter at all.
That confidence carried into the Q&A, where CEO Ari Bousbib addressed a question about chunky bookings or one-time items directly on the Q2 earnings call: “I have to tell you, in over 25 years of reporting earnings in these or other companies, I’ve never had as clean a quarter as this one all around.” But the release itself carried a wrinkle Bousbib didn’t address. GAAP diluted EPS of $1.53 missed estimates by 19.49%, and free cash flow of $360 million, though up 23% year over year, fell 9.75% short of what the Street had modeled.
Management responded by raising full-year guidance. IQVIA now expects 2026 revenue between $17.275 billion and $17.475 billion, up 7% at the midpoint, and adjusted diluted EPS between $12.80 and $13.00, up 8% at the midpoint. Third-quarter guidance calls for adjusted EPS between $3.19 and $3.29, and the company kept its December 2 Investor Day on the calendar as the next checkpoint for the bookings momentum to show up in reported numbers.
IQVIA’s bookings jumped 19.3% YoY to a 1.22x book-to-bill and trailing bookings hit $11.25 billion. Track the full backlog, review IQV’s full earnings on TIKR for free →
TIKR Prices IQVIA Stock at $363 by 2030 on Bookings-Driven Growth
TIKR’s mid-case model values IQVIA stock at $363 by December 2030, implying a 55% total return from the current price of $235, or 10% annualized over 4 years.
A 55% total return over four years is a return long-duration investors underwrite for accumulation, not a quick re-rating trade, and it says the model sees IQVIA stock as fairly priced today rather than deeply discounted.
The target is reachable because the bookings pipeline that drove second-quarter results, a 1.22 times book-to-bill ratio and trailing 12-month net new bookings up 12.9% year over year, has been accelerating for four straight quarters, and R&DS revenue growth over the next several years is contracted well before it shows up in the income statement. Management’s raised full-year guidance and its own description of the quarter as the cleanest in 25 years of reporting reinforce that the growth investors are paying for is already visible in the backlog, not projected onto it.
IQV stock carries a $363 mid-case target and a 10% annualized return path through 2030. See the full assumptions, explore the IQV valuation model on TIKR for free →
Should You Invest in IQVIA Holdings Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IQVIA Holdings Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IQVIA Holdings Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IQVIA stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
